Peer Review History: Nirmatrelvir-ritonavir for Treating COVID-19 Patients: A Case-Control Study

Editor(s):

(1) Prof. Ashish Anand, William Carey School of Osteopathic Medicine and University of Mississippi Medical Center, Mississippi, USA.

(2) Dr. Meng Ma, Anhui University, China.

Reviewers:

(1) Venkata Suresh Babu Agala, G H Raisoni University, India.

(2) Kaaviya. R, Sri Venkateshwaraa Medical College Hospital And Research Centre, India.

(3) Ali Faaeq Shaheed Samaraey, Imam Ja’afar Al-Sadiq University, Kirkuk, Iraq.

(4) Fariba Ghasemi, Islamic Azad University, Tehran, Iran.

Additional Reviewers:

(1) Ibtihal Abouchabaka, Cheikh Khalifa University Hospital, Casablanca, Morocco.

(2) N’guessan Deto Ursul Jean Paul, Félix Houphouet – Boigny University, Côte d’Ivoire.

(3) Subham Kapil, Career Point University, Hamirpur (HP), India.

(4) Yasmeen Riyadh Saeed, University of Hilla, Iraq.

(5) Zainab Sahib A. Quraish, Al Muthanna University, Iraq.

Additional Reviewers: (Comments received after deadline)

Open Peer Review Policy: Click Here

Specific Comment:

Average Peer review marks at initial stage: 8.25/10

Average Peer review marks at publication stage: 9/10

Peer Review History:


Stage 1 | Original Manuscript | File 1 | NA


Stage 2 | Peer Review Report_1 (Venkata Suresh Babu Agala, India) | File 1 | NA


Stage 2 | Peer Review Report_2 (Kaaviya. R, India) | File 1 | NA


Stage 2 | Peer Review Report_3 (Ali Faaeq Shaheed Samaraey, Iraq) | File 1 | NA


Stage 2 | Peer Review Report_4 (Fariba Ghasemi, Iran) | File 1 | NA


Stage 2 | Revised_MS_v1_and_Feedback_v1 | File 1 | File 2


Stage 3 | Comment_Editor_1_v1 | File 1 | NA


Stage 4 | Comment_Editor_2_v1 | File 1 | NA


Posted in Review History.